MedPath

A Multicenter Observational Study on the Development and Health Effects of Premature Ovarian Insufficiency

Not yet recruiting
Conditions
Premature Ovarian Insufficiency
Interventions
Drug: hormone replacement therapy
Registration Number
NCT06067529
Lead Sponsor
Women's Hospital School Of Medicine Zhejiang University
Brief Summary

Premature ovarian insufficiency (POI) refers to the occurrence of ovarian hypofunction in women before the age of 40, which seriously affects women's overall health and quality of life. However, there is currently insufficient understanding of the risk factors, pathogenesis, short-term and long-term health effects of POI, and the health effects of the disease, and there is a lack of high-quality evidence to support clinical diagnosis and treatment decisions. This study intends to construct a hospital-based multi-center POI case-control and prospective special disease cohort, after baseline assessment and follow-up monitoring, collect disease characteristics, lifestyle, social psychology, environmental and occupational exposure, biological samples and other data, aiming to observe POI The natural occurrence, progression and health impact of POI, clarify the risk factors of POI, evaluate the impact of POI on women's health and disease risk, and discuss the benefits, risks and options of HRT for POI patients. The results of this study will deepen and expand the understanding of the occurrence and development of POI and its short-term and long-term health effects, provide high-level evidence for optimizing POI prevention, diagnosis and treatment strategies, and establish a long-term management system, laying the foundation for interventional research.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
400
Inclusion Criteria
  • Age 18-39 years old
  • Meet POI diagnostic criteria
  • Volunteer to participate in this study and willing to cooperate with the investigation
Exclusion Criteria
  • Reproductive endocrine disease
  • Those receiving hormone supplementation and other steroid-containing drug therapy now or within half a year
  • Chromosomal abnormalities
  • Pregnancy and breastfeeding women
  • Uncontrolled endocrine system diseases
  • Uncontrolled cardiovascular system diseases
  • Uncontrolled autoimmune related diseases
  • Abnormal liver function
  • Abnormal kidney function
  • Abnormal coagulation function
  • Severe anemia
  • History of malignant tumors
  • History of radiotherapy
  • History of chemotherapy
  • Mental impairment
  • Cognitive impairment

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Premature ovarian insufficiency grouphormone replacement therapy-
Primary Outcome Measures
NameTimeMethod
bone density1 year

Dual Energy X-ray

procollagen type I carboxyl-terminal propeptide1 year

peripheral venous blood

Low-density lipoprotein cholesterol/High-density lipoprotein cholesterol1 year

peripheral venous blood

Estradiol/follicle stimulating hormone1 year

peripheral venous blood

fasting blood glucose1 year

peripheral venous blood

Secondary Outcome Measures
NameTimeMethod
free triiodothyronine/free thyroxine1 year

peripheral venous blood

Trial Locations

Locations (1)

Women's Hospital School of Medicine Zhejiang University

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath